173 related articles for article (PubMed ID: 2473984)
1. Activation of the contact system of coagulation by a monoclonal antibody directed against a neodeterminant in the heavy chain region of human coagulation factor XII (Hageman factor).
Nuijens JH; Huijbregts CC; Eerenberg-Belmer AJ; Meijers JC; Bouma BN; Hack CE
J Biol Chem; 1989 Aug; 264(22):12941-9. PubMed ID: 2473984
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein.
Ravon DM; Citarella F; Lubbers YT; Pascucci B; Hack CE
Blood; 1995 Dec; 86(11):4134-43. PubMed ID: 7492770
[TBL] [Abstract][Full Text] [Related]
3. A monoclonal antibody that inhibits activation of human Hageman factor (factor XII).
Small EJ; Katzmann JA; Tracy RP; Ratnoff OD; Goldsmith GH; Everson B
Blood; 1985 Jan; 65(1):202-10. PubMed ID: 3965048
[TBL] [Abstract][Full Text] [Related]
4. A monoclonal anti-human plasma prekallikrein antibody that inhibits activation of prekallikrein by factor XIIa on a surface.
Veloso D; Silver LD; Hahn S; Colman RW
Blood; 1987 Oct; 70(4):1053-62. PubMed ID: 2443201
[TBL] [Abstract][Full Text] [Related]
5. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
Revak SD; Cochrane CG; Griffin JH
J Clin Invest; 1977 Jun; 59(6):1167-75. PubMed ID: 864009
[TBL] [Abstract][Full Text] [Related]
6. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays.
Nuijens JH; Huijbregts CC; Cohen M; Navis GO; de Vries A; Eerenberg AJ; Bakker JC; Hack CE
Thromb Haemost; 1987 Aug; 58(2):778-85. PubMed ID: 2445044
[TBL] [Abstract][Full Text] [Related]
7. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces.
Citarella F; Ravon DM; Pascucci B; Felici A; Fantoni A; Hack CE
Eur J Biochem; 1996 May; 238(1):240-9. PubMed ID: 8665943
[TBL] [Abstract][Full Text] [Related]
8. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation.
Pixley RA; Stumpo LG; Birkmeyer K; Silver L; Colman RW
J Biol Chem; 1987 Jul; 262(21):10140-5. PubMed ID: 2440859
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody to human high-molecular-weight kininogen recognizes its prekallikrein binding site and inhibits its coagulant activity.
Reddigari SR; Kaplan AP
Blood; 1989 Aug; 74(2):695-702. PubMed ID: 2752143
[TBL] [Abstract][Full Text] [Related]
10. The second exon-encoded factor XII region is involved in the interaction of factor XII with factor XI and does not contribute to the binding site for negatively charged surfaces.
Citarella F; Fedele G; Roem D; Fantoni A; Hack CE
Blood; 1998 Dec; 92(11):4198-206. PubMed ID: 9834224
[TBL] [Abstract][Full Text] [Related]
11. Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII--an immunochemical and homology modeling approach.
Citarella F; te Velthuis H; Helmer-Citterich M; Hack CE
Thromb Haemost; 2000 Dec; 84(6):1057-65. PubMed ID: 11154114
[TBL] [Abstract][Full Text] [Related]
12. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor.
Scott CF; Silver LD; Schapira M; Colman RW
J Clin Invest; 1984 Apr; 73(4):954-62. PubMed ID: 6561202
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional characterization of factor XII.
Tans G; Rosing J
Semin Thromb Hemost; 1987 Jan; 13(1):1-14. PubMed ID: 3551074
[TBL] [Abstract][Full Text] [Related]
14. Initiation of contact activation by sulfatides.
Tans G; Griffin JH
Adv Exp Med Biol; 1983; 156():63-72. PubMed ID: 6602464
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP; Joseph K
Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of surface-mediated activation of bovine Factor XII and prekallikrein.
Sugo T; Ohno Y; Shimada T; Kato H; Iwanaga S
Adv Exp Med Biol; 1983; 156():87-107. PubMed ID: 6602465
[TBL] [Abstract][Full Text] [Related]
17. The contact activation mechanism in human plasma: activation induced by dextran sulfate.
van der Graaf F; Keus FJ; Vlooswijk RA; Bouma BN
Blood; 1982 Jun; 59(6):1225-33. PubMed ID: 6177360
[TBL] [Abstract][Full Text] [Related]
18. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII).
Griffin JH
Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1998-2002. PubMed ID: 273926
[TBL] [Abstract][Full Text] [Related]
19. Kinetic studies on surface-mediated activation of bovine factor XII and prekallikrein. Effects of kaolin and high-Mr kininogen on the activation reactions.
Sugo T; Kato H; Iwanaga S; Takada K; Sakakibara S
Eur J Biochem; 1985 Jan; 146(1):43-50. PubMed ID: 3871394
[TBL] [Abstract][Full Text] [Related]
20. Localization of distinct functional domains on prekallikrein for interaction with both high molecular weight kininogen and activated factor XII in a 28-kDa fragment (amino acids 141-371).
Page JD; Colman RW
J Biol Chem; 1991 May; 266(13):8143-8. PubMed ID: 1708772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
